A phase 3 clinical trial of an investigational oral treatment is now enrolling adults, 18 to 75 years of age, living with non-infectious uveitis (NIU).

NIU is an inflammatory eye condition caused by the body’s immune response to another disease or injury to the eye. NIU may affect one or both eyes and cause pain, swelling, floaters, and vision loss. These symptoms can worsen over time and impact quality of life. While treatments are available, they can cause serious side effects and may not work for everyone. Researchers continue to develop potential new treatments for people living with NIU.

The CLARITY Study is evaluating an investigational oral medicine called brepocitinib compared with placebo in adults 18 to 75 years of age with inflammation (uveitis) that is not due to infection and affects the back or middle of the eye, or multiple parts of the eye. These conditions collectively are called non-infectious uveitis (NIU) with posterior, intermediate, or panuveitis, or non-anterior NIU. Brepocitinib is investigational because it is not yet approved for use outside of clinical trials. This study will determine if brepocitinib reduces inflammation in NIU, improves symptoms, and is safe for use in this disease.

Participating in this study is voluntary, and you can choose to leave the study at any time. There is no cost to participate, and compensation for study-related time and expenses may be available. Travel coordination services are also available.

You may be eligible to participate in the CLARITY Study if you are:

Other eligibility criteria apply. The study physician will determine if this study is right for you based on all criteria.

Clinical trials like the CLARITY Study depend on the participation of patients. By choosing to take part in this study, you will contribute to research that could make a difference for others living with NIU. Thank you for considering this important study.

If you are interested in participating, the study physician will complete exams and tests to determine if you are eligible.

Screening may include:

If you qualify for the study, you will start a course of prednisone (an oral corticosteroid), and you will also be randomly assigned to receive either brepocitinib or placebo. The placebo is a tablet that looks identical to brepocitinib but does not contain any active ingredients. Neither you nor the study physician will know to which group you are assigned.

You will take once daily doses of brepocitinib or placebo for up to 48 weeks (about 11 months) and may attend at least 12 appointments during that time.

After completing the Study Treatment Period (as above), or if your condition substantially worsens before completing the Study Treatment Period, you may be able to continue in the study during an “Open-Label Treatment” period. During this part of the study, all participants will take brepocitinib and no placebo will be given. You will take once daily doses of brepocitinib for 48 weeks (about 11 months) and will attend at least six appointments during this time.

28 days after your last dose of brepocitinib, you will attend a follow-up appointment so the study physician can do final health checks.

Below is a list of locations for the CLARITY Study.